We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva Systems (VEEV) Stock Declines While Market Improves: Some Information for Investors
Read MoreHide Full Article
Veeva Systems (VEEV - Free Report) closed at $227.11 in the latest trading session, marking a -0.26% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.74%. At the same time, the Dow added 0.05%, and the tech-heavy Nasdaq gained 1.26%.
The provider of cloud-based software services for the life sciences industry's shares have seen a decrease of 4.11% over the last month, surpassing the Medical sector's loss of 7.7% and the S&P 500's loss of 4.77%.
Analysts and investors alike will be keeping a close eye on the performance of Veeva Systems in its upcoming earnings disclosure. The company is forecasted to report an EPS of $1.74, showcasing a 16% upward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $727.99 million, up 11.94% from the prior-year quarter.
VEEV's full-year Zacks Consensus Estimates are calling for earnings of $7.30 per share and revenue of $3.05 billion. These results would represent year-over-year changes of +10.61% and +10.99%, respectively.
Investors should also pay attention to any latest changes in analyst estimates for Veeva Systems. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.18% higher. Veeva Systems is currently a Zacks Rank #2 (Buy).
Investors should also note Veeva Systems's current valuation metrics, including its Forward P/E ratio of 31.2. This indicates a premium in contrast to its industry's Forward P/E of 24.39.
We can also see that VEEV currently has a PEG ratio of 1.19. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As of the close of trade yesterday, the Medical Info Systems industry held an average PEG ratio of 2.92.
The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 56, finds itself in the top 23% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Veeva Systems (VEEV) Stock Declines While Market Improves: Some Information for Investors
Veeva Systems (VEEV - Free Report) closed at $227.11 in the latest trading session, marking a -0.26% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.74%. At the same time, the Dow added 0.05%, and the tech-heavy Nasdaq gained 1.26%.
The provider of cloud-based software services for the life sciences industry's shares have seen a decrease of 4.11% over the last month, surpassing the Medical sector's loss of 7.7% and the S&P 500's loss of 4.77%.
Analysts and investors alike will be keeping a close eye on the performance of Veeva Systems in its upcoming earnings disclosure. The company is forecasted to report an EPS of $1.74, showcasing a 16% upward movement from the corresponding quarter of the prior year. Meanwhile, our latest consensus estimate is calling for revenue of $727.99 million, up 11.94% from the prior-year quarter.
VEEV's full-year Zacks Consensus Estimates are calling for earnings of $7.30 per share and revenue of $3.05 billion. These results would represent year-over-year changes of +10.61% and +10.99%, respectively.
Investors should also pay attention to any latest changes in analyst estimates for Veeva Systems. Recent revisions tend to reflect the latest near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.18% higher. Veeva Systems is currently a Zacks Rank #2 (Buy).
Investors should also note Veeva Systems's current valuation metrics, including its Forward P/E ratio of 31.2. This indicates a premium in contrast to its industry's Forward P/E of 24.39.
We can also see that VEEV currently has a PEG ratio of 1.19. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. As of the close of trade yesterday, the Medical Info Systems industry held an average PEG ratio of 2.92.
The Medical Info Systems industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 56, finds itself in the top 23% echelons of all 250+ industries.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.